Navigation Links
IR BioSciences Announces Promising Data from Study of Its Compound,Homspera

As the World Health Organization notes, when the next pandemic virus strain emerges, it could circle the globe in three months and cause significant morbidity and mortality. Subsequent waves of virus spread would add to the economic and social dislocation. Whatever drugs or vaccines are available at the start of the pandemic must be sufficient to vaccinate or treat the maximum number of people within weeks or at most, a few months. Adjuvants provide the capability to maximize the number of individuals who can be treated with a limited amount of vaccine.

In conjunction with Homspera's previously reported capability to decrease influenza viral titers and symptoms in the cotton rat model of influenza, the adjuvant capability makes Homspera a highly desirable candidate product for use in influenza. ImmuneRegen BioSciences will continue to explore this capability of its Homspera compound.

About ImmuneRegen BioSciences, Inc.

IR BioSciences Holdings Inc., through its wholly owned subsidiary ImmuneRegen BioSciences, Inc., is a development stage biotechnology company focused on the research and development of Homspera(TM) and its derivatives Radilex(TM) and Viprovex(TM), which are designed to be used as countermeasures for multiple homeland security bioterrorism threats. Homspera is derived from modified Substance P, a naturally occurring peptide immunomodulator and homeostatic compound with the dual effect of improving pulmonary function and the stimulation of the human immune system. For more information, please visit the company's website at www.immuneregen.com.

Statements about the Company's future expectations, including statements about the potential for the Company's drug candidates, science and technology, and all other statements in this press release other than historical facts, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Sec
'"/>




Page: 1 2 3 4

Related medicine technology :

1. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
2. YM BioSciences Announces Preclinical Data Confirming Nimotuzumab Binds to the EGF Receptor and Potentiates Radiotherapy
3. Sangamo BioSciences Announces Presentation of Phase 1 ZFP Therapeutic Data at American Diabetes Association Meeting
4. Sangamo BioSciences Announces Presentation of ZFP Therapeutic Data From Nerve Regeneration Program at American Society for Neural Therapy and Repair Meeting
5. YM BioSciences Reports AeroLEF Randomized Phase IIb Trial Meets Primary Endpoint in Patients with Post-Surgical Pain
6. ImmuneRegen BioSciences Announces Promising Data on Homspera Suggesting Potential as a Co-Therapeutic Agent
7. Study in Cell by Magen BioSciences Co-Founder David E. Fisher Identifies New Roles in Skin Cancer Prevention for Key Tumor Suppressor Protein
8. IR BioSciences Announces Data Demonstrating Radilex Stimulation of Stem Cells Results in Hematopoietic Recovery Following Lethal Irradiation
9. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
10. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
Post Your Comments:
(Date:7/22/2014)... Elekta (NSE:EKTAb) and Royal Philips ... Foundation Trust ( Manchester, UK ), a ... is to develop the clinical value of an integrated ... a system would, in principle, improve the practice of ... "The Christie was an essential participant in the ...
(Date:7/22/2014)... 2014 Sanofi Pasteur, the vaccines division of Sanofi ... that the first lots of Fluzone ® (Influenza Vaccine) ... by the U.S. Food and Drug Administration (FDA) for distribution. ... first of at least 65 million doses of seasonal influenza ... U.S. health care providers and pharmacies in August. ...
(Date:7/22/2014)... SAN DIEGO , July 22, 2014  Halozyme ... that it has resumed enrollment and dosing of patients ... PEGPH20 in patients with pancreatic cancer under the revised ... PEGPH20 is an investigational PEGylated form of Halozyme,s proprietary ... of tumors that accumulate hyaluronan. "Our ...
Breaking Medicine Technology:The Christie Hospital joins Elekta and Philips research consortium to develop MRI-guided radiation therapy system for cancer treatment 2The Christie Hospital joins Elekta and Philips research consortium to develop MRI-guided radiation therapy system for cancer treatment 3The Christie Hospital joins Elekta and Philips research consortium to develop MRI-guided radiation therapy system for cancer treatment 4Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 2Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 3Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 4Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 5Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 6Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 7Halozyme Resumes Patient Enrollment And Dosing In PEGPH20 Clinical Program In Pancreatic Cancer 2Halozyme Resumes Patient Enrollment And Dosing In PEGPH20 Clinical Program In Pancreatic Cancer 3
... ALL Study Group Presented Data at the 14th Congress ... in Patients with Minimal Residual Disease , , ... MITI ), a biopharmaceutical company developing novel, proprietary antibodies ... announced that the German Multicenter ALL Study Group (GMALL) ...
... 2 data sets to be released-- , ... clinical trials in patients with blepharospasm and cervical dystonia -- ... -- were presented at the Movement Disorder Society (MDS) 13th ... by Merz Pharmaceuticals, which plans to file a Biologic License ...
Cached Medicine Technology:Micromet's Blinatumomab Achieves Primary Endpoint in Phase 2 Study with Acute Lymphoblastic Leukemia Patients 2Micromet's Blinatumomab Achieves Primary Endpoint in Phase 2 Study with Acute Lymphoblastic Leukemia Patients 3Micromet's Blinatumomab Achieves Primary Endpoint in Phase 2 Study with Acute Lymphoblastic Leukemia Patients 4Micromet's Blinatumomab Achieves Primary Endpoint in Phase 2 Study with Acute Lymphoblastic Leukemia Patients 5Merz Pharmaceuticals Announces Results of Clinical Trials with NT-201(Botulinum neurotoxin type A free from complexing proteins) at Annual Movement Disorders Society Meeting 2Merz Pharmaceuticals Announces Results of Clinical Trials with NT-201(Botulinum neurotoxin type A free from complexing proteins) at Annual Movement Disorders Society Meeting 3Merz Pharmaceuticals Announces Results of Clinical Trials with NT-201(Botulinum neurotoxin type A free from complexing proteins) at Annual Movement Disorders Society Meeting 4
(Date:7/23/2014)... Hemodialysis equipment is the most widely used ... acute or chronic renal failure. , The Chinese hemodialysis ... European, American and Japanese enterprises. In 2013, the import ... growing demand for hemodialysis equipment in China, its import ... in 2009-2013. Germany, Sweden and Japan as the main ...
(Date:7/23/2014)... month of July, LunaDress, a well-known wedding dress manufacturer and ... hosting a couple of promotions on its website. Recently, the ... wedding dresses for the UK market . The fresh range ... are now offered with huge discounts, from 20 to 70 ... suppliers, LunaDress is always making full efforts to offer classy ...
(Date:7/23/2014)... 23, 2014 World Gardens Café, the ... healthy gourmet cuisine, received rave reviews last week when ... Mixer. Mixer attendees were amazed that healthy food could ... World Gardens Café, the premier provider of delicious and ... booth at Dave Linden’s LA’s Largest Mixer. Attendees who ...
(Date:7/23/2014)... 2014 Sanuvox has produced a ... of the company’s latest system designed for hospital ... System uses a primary and secondary unit to ... ‘C’ energy controlling (6 log reduction) drug-resistant microorganisms ... than 10 minutes in a standard patient hospital ...
(Date:7/23/2014)... Low enrollment and higher-than-expected administrative costs ... up with alternative means to becoming self-sustaining. Industry ... accomplish this in the July 17 issue of ... , “We never expected the operating budgets would ... an attorney at the law firm Venable LLP ...
Breaking Medicine News(10 mins):Health News:China Hemodialysis Equipment Market (Import & Export) Report 2013-2016 Now Available at ChinaMarketResearchReports.com 2Health News:China Hemodialysis Equipment Market (Import & Export) Report 2013-2016 Now Available at ChinaMarketResearchReports.com 3Health News:China Hemodialysis Equipment Market (Import & Export) Report 2013-2016 Now Available at ChinaMarketResearchReports.com 4Health News:LunaDress Continues To Enrich Product Line By Offering Short Summer Beach Wedding Dresses 2Health News:Healthy Food Gets Rave Reviews at LA’s Largest Mixer 2Health News:Sanuvox Produces ASEPTIX² Movie Showcasing the Feature Benefits of the Company’s Latest Flagship Hospital Surface Disinfection System 2Health News:Industry Observers Tell AIS They Predict Changes to Exchange User Fees, Platforms 2Health News:Industry Observers Tell AIS They Predict Changes to Exchange User Fees, Platforms 3
... from the University of North Carolina at Chapel Hill suggests that ... morning or later in the afternoon can influence the onset ... exposure to UV radiation in the morning increased the risk of ... Although mice and humans both reside on a 24-hour day, the ...
... Rockville, MD -- Physical activity may be what the ... developing glaucoma. According to a recently published scientific paper, ... long-term beneficial impact on low ocular perfusion pressure (OPP), ... the Investigative Ophthalmology & Visual Science journal ...
... LANSING, Mich. -- Despite the fact mental health problems ... combined, about two-thirds of mental health patients are cared ... Additionally, even larger numbers of other patients regularly ... A new five-year, $1 million grant allows Michigan State ...
... related macular degeneration (AMD) is the leading cause of ... identified several relatively common genetic variants which together predict ... number of persons without the disease also have these ... able to clearly show a specific rare mutation called ...
... study published today in the journal Nature Genetics ... Lieb, PhD, present experiments supporting a longstanding hypothesis that ... of the X chromosome. The finding provides clarity to ... with more information to interpret experiments involving genetic measurements ...
... FESC, from the University of Padua, Italy, explains, "To ... from all the different imaging modalities, not just Echo. ... is that we want to become more patient oriented, ... the most appropriate technology to address individual clinical questions." ...
Cached Medicine News:Health News:Morning UV exposure may be less damaging to the skin 2Health News:Physical fitness could have a positive effect on eye health 2Health News:Residency program focuses on overlooked mental health needs 2Health News:Researchers ID genetic mutation associated with high risk of age-related macular degeneration 2Health News:Study confirms males and females have at least 1 thing in common: Upregulating X 2Health News:Congress alert: EUROECHO and Other Imaging Modalities: New patient emphasis 2Health News:Congress alert: EUROECHO and Other Imaging Modalities: New patient emphasis 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: